

Supplementary Section

HE4 overexpression promotes ovarian tumor growth.

Richard G. Moore¹, Emily K Hill¹, Timothy Horan¹, Naohiro Yano², KyuKwang Kim¹, Shannon MacLaughlan³, Geralyn Lambert-Messerlian⁴, YiTang Don Tseng², Craig M. Miller¹, James F Padbury², Thilo S Lange^{1,5}, Rakesh K Singh¹.

¹Molecular Therapeutics Laboratory, Program in Women's Oncology, Women and Infants' Hospital of Rhode Island, Alpert Medical School, Brown University, Providence, RI 02903, USA.

² Department of Pediatrics, Women and Infants' Hospital of Rhode Island, Alpert Medical School, Brown University, Providence, RI 02903, USA.


³ Stanford School of Medicine, Gynecology Oncology, 300 Pasteur Dr. A370 Stanford, CA 94305, USA.

⁴ Prenatal and Special Testing, Department of Pathology, Women and Infants' Hospital of Rhode Island, Alpert Medical School, Brown University, Providence, Rhode Island, USA.


⁵ Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI 02912, USA

Corresponding Authors: Richard G Moore MD and Rakesh Singh, PhD
Molecular Therapeutics Laboratory, Program in Women's Oncology, Women and Infants' Hospital of Rhode Island, Alpert Medical School, Brown University, Providence, RI 02903, USA. Tel: 401-274-1122 ext 8062, Fax: 401-277-3617.
Emails: rmoores@wihri.org and rsingh@wihri.org .

Supplementary Figures and figure legends:



Supplementary Figure 1: Survival analysis of ovarian cancer patients. (A) Kaplan-Meier survival curve of 89 ovarian cancer patients show decreased survival for grade-III/IV patients (n=68) compared to patients diagnosed with stage I/II (n=21) ($p=0.0002$). (B) Post-menopausal patients (n=78) died earlier than premenopausal patients (n=11) ($p=0.0297$).



Supplementary Figure 2: HE4 overexpression promotes chemoresistance.

(A) RT-PCR of HE4 overexpressing SKOV-3 clones. (B) MTS based cell viability assay of WT SKOV-3 and SKOV-3 clones treated with Paclitaxel for 24 h revealed increased resistance by HE4 overexpressing cells. (C) HE4 cellular (lysate) and media secretion (SN; supernatant, 24 h) levels in WT OVCAR-3, null vector clone and stably HE4 overexpressing OVCAR-8 HE4C5 clone were determined by ELISA. (D) Cell viability assay of WT OVCAR-8, null vector clone and HE4 overexpressing OVCAR-8 clones (HE4C5, HE4C6) treated with Cisplatin for 24 h revealed increased resistance by HE4 overexpressing cells.

Un-cropped Immunoblots:

